Breakdown | |||||
TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
6.24B | 6.26B | 6.04B | 5.81B | 4.92B | 4.43B | Gross Profit |
2.34B | 2.35B | 2.43B | 2.43B | 2.11B | 1.91B | EBIT |
13.60M | -1.18B | 225.56M | 266.07M | 194.40M | 110.60M | EBITDA |
193.01M | -971.83M | 407.75M | 464.20M | 383.76M | 316.84M | Net Income Common Stockholders |
-110.55M | -1.28B | 90.80M | 164.42M | -38.30M | -106.42M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
178.20M | 125.43M | 201.90M | 211.60M | 111.40M | 148.78M | Total Assets |
1.65B | 5.36B | 6.61B | 6.50B | 6.08B | 6.16B | Total Debt |
534.28M | 3.03B | 3.11B | 3.02B | 2.99B | 4.69B | Net Debt |
356.08M | 2.90B | 2.91B | 2.81B | 2.88B | 4.54B | Total Liabilities |
751.22M | 4.18B | 4.23B | 4.24B | 4.02B | 5.59B | Stockholders Equity |
909.95M | 1.18B | 2.38B | 2.27B | 2.07B | 569.39M |
Cash Flow | Free Cash Flow | ||||
92.78M | -9.88M | 67.98M | 119.11M | 109.06M | -47.02M | Operating Cash Flow |
232.88M | 215.72M | 346.00M | 358.21M | 268.62M | 110.34M | Investing Cash Flow |
-140.80M | -207.44M | -320.32M | -237.08M | -157.19M | -139.04M | Financing Cash Flow |
-113.30M | -85.35M | -33.84M | -18.78M | -146.61M | -3.07M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $14.58B | 39.19 | 101.78% | ― | 6.40% | 891.13% | |
73 Outperform | $30.88B | 16.81 | 34.29% | 1.66% | 2.79% | -23.30% | |
67 Neutral | $15.99B | 17.81 | 20.69% | 3.53% | 1.71% | -30.78% | |
60 Neutral | $13.10B | 14.48 | 31.63% | 6.08% | -4.43% | -24.58% | |
60 Neutral | $6.54B | 11.34 | 3.27% | 4.27% | 2.37% | -20.86% | |
54 Neutral | $856.97M | ― | -8.86% | ― | -2.22% | 92.17% | |
54 Neutral | $11.97B | 100.83 | 4.19% | ― | -27.50% | 1150.23% |
Petco Health and Wellness Company reported its financial results for the fourth quarter and full year 2024, showing a decrease in net revenue and gross profit compared to the previous year. Despite these declines, the company reduced its GAAP net loss significantly and improved its free cash flow. CEO Joel Anderson expressed confidence in the new leadership team’s ability to drive double-digit adjusted EBITDA growth in 2025, positioning the company for sustainable profitable growth.
On February 18, 2025, Petco Health and Wellness Company announced a leadership change with Sabrina Simmons succeeding Brian LaRose as Chief Financial Officer, effective February 17, 2025. Mr. LaRose transitioned to a non-officer role and will remain with the company until April 30, 2025, to assist with the transition. He entered into a transition and separation agreement, receiving a lump sum payment and other benefits as part of his departure package.
On February 17, 2025, Petco Health and Wellness Company appointed Sabrina Simmons as Chief Financial Officer, succeeding Brian LaRose who will remain in an advisory role until April 30, 2025. Petco also announced the appointments of Michael Romanko as Chief Customer and Product Officer, and Jack Stout as Chief Merchandising Officer, effective February 24, 2025. These leadership changes are part of Petco’s strategy to accelerate operational improvements and return to profitable growth, leveraging the extensive retail expertise of the new appointees.